{"id":"cefalexin","rwe":[{"pmid":"41759466","year":"2025","title":"Epidemiological investigation and antimicrobial resistance profiling of Salmonella in broiler chickens with assessment of Lactococcus lactis probiotic therapy.","finding":"","journal":"Poultry science","studyType":"Clinical Study"},{"pmid":"41744033","year":"2026","title":"Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence.","finding":"","journal":"The Journal of antimicrobial chemotherapy","studyType":"Clinical Study"},{"pmid":"41719646","year":"2026","title":"Structure-dependent transformation of cephalosporin antibiotics at MnO(2) surface mediated by iodide and formation of highly toxic iodinated products.","finding":"","journal":"Water research","studyType":"Clinical Study"},{"pmid":"41602617","year":"2025","title":"Antimicrobial use in breeding kennels and antimicrobial resistance profile of Escherichia coli and Staphylococcus pseudintermedius isolated from healthy breeding bitches in Northern Italy.","finding":"","journal":"Frontiers in veterinary science","studyType":"Clinical Study"},{"pmid":"41485905","year":"2025","title":"Trends in Group A Streptococcus Isolation and Antimicrobial Susceptibility in a Pediatric Population (2021-2023): Comparison with Six Previous Surveys.","finding":"","journal":"Japanese journal of infectious diseases","studyType":"Clinical Study"}],"tags":[{"label":"Cephalosporin Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Solute carrier family 15 member 2","category":"target"},{"label":"SLC15A2","category":"gene"},{"label":"J01DB01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"For Suspension","category":"form"},{"label":"Powder","category":"form"},{"label":"Suspension","category":"form"},{"label":"Active","category":"status"},{"label":"Acute otitis media","category":"indication"},{"label":"Bacterial urinary infection","category":"indication"},{"label":"Escherichia coli urinary tract infection","category":"indication"},{"label":"Haemophilus Influenzae Acute Otitis Media","category":"indication"},{"label":"Infection due to Staphylococcus aureus","category":"indication"},{"label":"Infection of bone","category":"indication"},{"label":"Shionogi Inc","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":1354.205,"date":"","count":1446,"signal":"Drug hypersensitivity","source":"DrugCentral FAERS","actionTaken":"Reported 1,446 times (LLR=1354)"},{"llr":220.652,"date":"","count":89,"signal":"Type IV hypersensitivity reaction","source":"DrugCentral FAERS","actionTaken":"Reported 89 times (LLR=221)"},{"llr":219.462,"date":"","count":85,"signal":"Cross sensitivity reaction","source":"DrugCentral FAERS","actionTaken":"Reported 85 times (LLR=219)"},{"llr":209.855,"date":"","count":329,"signal":"Cellulitis","source":"DrugCentral FAERS","actionTaken":"Reported 329 times (LLR=210)"},{"llr":147.753,"date":"","count":252,"signal":"Chronic kidney disease","source":"DrugCentral FAERS","actionTaken":"Reported 252 times (LLR=148)"},{"llr":131.575,"date":"","count":53,"signal":"Loss of employment","source":"DrugCentral FAERS","actionTaken":"Reported 53 times (LLR=132)"},{"llr":116.277,"date":"","count":467,"signal":"Urinary tract infection","source":"DrugCentral FAERS","actionTaken":"Reported 467 times (LLR=116)"},{"llr":115.966,"date":"","count":862,"signal":"Rash","source":"DrugCentral FAERS","actionTaken":"Reported 862 times (LLR=116)"},{"llr":115.333,"date":"","count":55,"signal":"Oesophageal spasm","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=115)"},{"llr":108.838,"date":"","count":34,"signal":"Urinary tract discomfort","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=109)"},{"llr":105.211,"date":"","count":55,"signal":"Oesophageal pain","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=105)"},{"llr":103.2,"date":"","count":6,"signal":"Pemphigus","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=103)"},{"llr":102.411,"date":"","count":8,"signal":"Synovitis","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=102)"},{"llr":101.452,"date":"","count":34,"signal":"Alveolar osteitis","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=101)"},{"llr":93.701,"date":"","count":44,"signal":"Infusion related reaction","source":"DrugCentral FAERS","actionTaken":"Reported 44 times (LLR=94)"}],"drugInteractions":[{"url":"/drug/metformin","drug":"metformin","action":"Monitor closely","effect":"May interact with Cephalexin, Metformin Hydrochloride","source":"DrugCentral","drugSlug":"metformin"},{"url":"/drug/warfarin","drug":"warfarin","action":"Monitor closely","effect":"May interact with Cephalexin, Warfarin","source":"DrugCentral","drugSlug":"warfarin"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"","severity":"most frequent","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"rare","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"rare","organSystem":""},{"effect":"Urticaria","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Gastritis","drugRate":"","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"","severity":"common","organSystem":""},{"effect":"Genital pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Anal pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Genital moniliasis","drugRate":"","severity":"common","organSystem":""},{"effect":"Vaginitis","drugRate":"","severity":"common","organSystem":""},{"effect":"Vaginal discharge","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Agitation","drugRate":"","severity":"common","organSystem":""},{"effect":"Confusion","drugRate":"","severity":"common","organSystem":""},{"effect":"Hallucinations","drugRate":"","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Colitis","Kidney disease","Pseudomembranous enterocolitis"],"specialPopulations":{"Pregnancy":"Cephalexin should be used during pregnancy only if clearly needed. No adverse effects on fertility, fetal viability, fetal weight, or litter size were observed in animal studies.","Geriatric use":"No overall differences in safety or effectiveness were observed between elderly and younger patients. However, the risk of toxic reactions may be greater in patients with impaired renal function.","Paediatric use":"The safety and effectiveness of cephalexin in pediatric patients was established in clinical trials. Cephalexin capsules should only be used in children and adolescents capable of ingesting the capsule.","Renal impairment":"The risk of toxic reactions to this drug may be greater in patients with impaired renal function."},"seriousAdverseEvents":[{"effect":"Pseudomembranous colitis","drugRate":"","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Stevens-Johnson syndrome","drugRate":"","severity":"serious"},{"effect":"Toxic epidermal necrolysis","drugRate":"","severity":"serious"},{"effect":"Erythema multiforme","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Transient hepatitis","drugRate":"","severity":"serious"},{"effect":"Cholestatic jaundice","drugRate":"","severity":"serious"},{"effect":"Reversible interstitial nephritis","drugRate":"","severity":"serious"},{"effect":"Aplastic anemia","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Shionogi","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=cefalexin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:28:49.838339+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:28:56.708936+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cefalexin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:28:57.384060+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial penicillin-binding protein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:28:58.018454+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200544/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:28:57.926790+00:00"}},"allNames":"keflex","offLabel":[],"synonyms":["cefalexin hydrochloride","cephalexin","cefalexin","cephacillin","cephalexin anhydrous","cephalexin hydrochloride","cephalexin hydrate","cefalexin HCl","cephalexin HCl"],"timeline":[{"date":"1971-01-04","type":"positive","source":"DrugCentral","milestone":"FDA approval (Shionogi Inc)"}],"aiSummary":"Keflex (cefalexin) is a cephalosporin antibiotic developed by Shionogi Inc. in 1971. It targets the solute carrier family 15 member 2 and is effective against a range of bacterial infections, including urinary tract infections, skin infections, and bone infections. Keflex is a small molecule modality with a bioavailability of 90% and a half-life of 0.57 hours. It is currently owned by Shionogi Inc. and is used to treat various bacterial infections. Key safety considerations include its potential to cause allergic reactions and gastrointestinal side effects.","brandName":"Keflex","ecosystem":[{"indication":"Acute otitis media","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"},{"name":"cefixime","slug":"cefixime","company":""}],"globalPrevalence":709000000},{"indication":"Bacterial urinary infection","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"avibactam","slug":"avibactam","company":"Cerexa Inc"}],"globalPrevalence":null},{"indication":"Escherichia coli urinary tract infection","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"},{"name":"betaine","slug":"betaine","company":"Rare Dis Therap"}],"globalPrevalence":null},{"indication":"Haemophilus Influenzae Acute Otitis Media","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"cefixime","slug":"cefixime","company":""}],"globalPrevalence":null},{"indication":"Infection due to Staphylococcus aureus","otherDrugs":[{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"}],"globalPrevalence":null},{"indication":"Infection of bone","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"cefalotin","slug":"cefalotin","company":"Lilly"},{"name":"cefapirin","slug":"cefapirin","company":"Apothecon"}],"globalPrevalence":null},{"indication":"Infection of skin AND/OR subcutaneous tissue","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"amphotericin B","slug":"amphotericin-b","company":"Apothecon"}],"globalPrevalence":null},{"indication":"Infectious disorder of joint","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"cefalotin","slug":"cefalotin","company":"Lilly"},{"name":"cefapirin","slug":"cefapirin","company":"Apothecon"}],"globalPrevalence":null}],"mechanism":{"target":"Solute carrier family 15 member 2","novelty":"First-in-class","targets":[{"gene":"SLC15A2","source":"DrugCentral","target":"Solute carrier family 15 member 2","protein":"Solute carrier family 15 member 2"}],"modality":"Small Molecule","drugClass":"Cephalosporin Antibacterial","explanation":"","oneSentence":"","technicalDetail":"Keflex exerts its antibacterial effects by binding to and inhibiting the activity of penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. This results in the disruption of the bacterial cell wall, ultimately leading to cell lysis and death."},"commercial":{"launchDate":"1971","_launchSource":"DrugCentral (FDA 1971-01-04, SHIONOGI INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/571","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=cefalexin","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cefalexin","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:12:30.384296","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:28:59.768490+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cefalotin","drugSlug":"cefalotin","fdaApproval":"1974-12-18","relationship":"same-class"},{"drugName":"cefazolin","drugSlug":"cefazolin","fdaApproval":"1973-10-04","genericCount":20,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefadroxil","drugSlug":"cefadroxil","fdaApproval":"1978-02-17","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefapirin","drugSlug":"cefapirin","fdaApproval":"1974-03-12","relationship":"same-class"},{"drugName":"cefradine","drugSlug":"cefradine","fdaApproval":"1974-08-19","relationship":"same-class"}],"genericName":"cefalexin","indications":{"approved":[{"name":"Acute otitis media","source":"DrugCentral","snomedId":3110003,"regulator":"FDA","eligibility":"Children and adults with otitis media due to susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis","usPrevalence":null,"globalPrevalence":709000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2026 (PMID:41640273)"},{"name":"Bacterial urinary infection","source":"DrugCentral","snomedId":312124009,"regulator":"FDA","eligibility":"Adults with genitourinary tract infections due to susceptible strains of Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae"},{"name":"Escherichia coli urinary tract infection","source":"DrugCentral","snomedId":301011002,"regulator":"FDA","eligibility":"Adults with genitourinary tract infections due to susceptible strains of Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae"},{"name":"Haemophilus Influenzae Acute Otitis Media","source":"DrugCentral","snomedId":19021002,"regulator":"FDA","eligibility":"Children and adults with otitis media due to susceptible strains of Haemophilus influenzae"},{"name":"Infection due to Staphylococcus aureus","source":"DrugCentral","snomedId":406602003,"regulator":"FDA","eligibility":"Adults and children with skin and skin structure infections, bone infections, and other infections due to susceptible strains of Staphylococcus aureus"},{"name":"Infection of bone","source":"DrugCentral","snomedId":111253001,"regulator":"FDA","eligibility":"Adults and children with bone infections due to susceptible strains of Staphylococcus aureus and/or Proteus mirabilis"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA","eligibility":"Adults and children with skin and skin structure infections due to susceptible strains of Staphylococcus aureus and/or Streptococcus pyogenes"},{"name":"Infectious disorder of joint","source":"DrugCentral","snomedId":363162000,"regulator":"FDA","eligibility":"Not specified"},{"name":"Infective otitis media","source":"DrugCentral","snomedId":312218008,"regulator":"FDA","eligibility":"Children and adults with otitis media due to susceptible strains of Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis"},{"name":"Klebsiella Prostatitis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults with acute prostatitis due to susceptible strains of Klebsiella pneumoniae"},{"name":"Klebsiella cystitis","source":"DrugCentral","snomedId":60867007,"regulator":"FDA"},{"name":"Moraxella Catarrhalis Acute Otitis Media","source":"DrugCentral","snomedId":703469002,"regulator":"FDA","usPrevalence":null,"globalPrevalence":709000000,"prevalenceMethod":"curated","prevalenceSource":"Influenza Other Respir Viruses, 2026 (PMID:41640273)"},{"name":"Osteomyelitis due to Staphylococcus aureus","source":"DrugCentral","snomedId":428783003,"regulator":"FDA"},{"name":"Pneumonia due to Streptococcus","source":"DrugCentral","snomedId":34020007,"regulator":"FDA"},{"name":"Prostatitis","source":"DrugCentral","snomedId":9713002,"regulator":"FDA"},{"name":"Proteus Prostatitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Proteus urinary tract infection","source":"DrugCentral","snomedId":301012009,"regulator":"FDA"},{"name":"Staphylococcus Acute Otitis Media","source":"DrugCentral","snomedId":703469002,"regulator":"FDA"},{"name":"Streptococcal tonsillitis","source":"DrugCentral","snomedId":41582007,"regulator":"FDA"},{"name":"Streptococcus Osteomyelitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Streptococcus pyogenes infection","source":"DrugCentral","snomedId":302809008,"regulator":"FDA"}],"offLabel":[{"name":"Bacterial Mastitis","source":"DrugCentral","drugName":"cefalexin","evidenceCount":62,"evidenceLevel":"strong"},{"name":"Diabetic Foot Infection Due to Gram-Positive Bacteria","source":"DrugCentral","drugName":"cefalexin","evidenceCount":2,"evidenceLevel":"emerging"},{"name":"Prevention of Bacterial Endocarditis","source":"DrugCentral","drugName":"cefalexin","evidenceCount":13,"evidenceLevel":"moderate"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"cefalotin","brandName":"cefalotin","genericName":"cefalotin","approvalYear":"1974","relationship":"same-class"},{"drugId":"cefazolin","brandName":"cefazolin","genericName":"cefazolin","approvalYear":"1973","relationship":"same-class"},{"drugId":"cefadroxil","brandName":"cefadroxil","genericName":"cefadroxil","approvalYear":"1978","relationship":"same-class"},{"drugId":"cefapirin","brandName":"cefapirin","genericName":"cefapirin","approvalYear":"1974","relationship":"same-class"},{"drugId":"cefradine","brandName":"cefradine","genericName":"cefradine","approvalYear":"1974","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07300670","phase":"PHASE1","title":"The Effect of Losartan on Cephalexin","status":"RECRUITING","sponsor":"Aleksi Tornio","startDate":"2026-03-04","conditions":["Possible Interaction Between Losartan and Cephalexin","Healthy"],"enrollment":12,"completionDate":"2026-05-08"},{"nctId":"NCT04580472","phase":"PHASE4","title":"Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Carilion Clinic","startDate":"2020-10-01","conditions":["Surgical Site Infection"],"enrollment":574,"completionDate":"2026-09"},{"nctId":"NCT06406114","phase":"PHASE2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-05","conditions":["Drug Allergy","Cephalosporin Allergy","Drug Hypersensitivity","Antibiotic Allergy","Beta Lactam Adverse Reaction","Drug-Induced Anaphylaxis","Cephalosporin Reaction"],"enrollment":300,"completionDate":"2028-12-31"},{"nctId":"NCT05020574","phase":"PHASE2","title":"Microbiome and Association With Implant Infections","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-09-28","conditions":["Breast Cancer","Breast Cancer Female","Genetic Predisposition to Disease"],"enrollment":200,"completionDate":"2026-12-31"},{"nctId":"NCT01631617","phase":"PHASE2","title":"Effects of Treatments on Atopic Dermatitis","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2012-09-18","conditions":["Eczema","Dermatitis","Skin Diseases, Genetic","Dermatitis, Atopic","Skin Diseases"],"enrollment":130,"completionDate":"2027-01-01"},{"nctId":"NCT06080698","phase":"NA","title":"Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-02-22","conditions":["Gram-negative Bacteremia"],"enrollment":1030,"completionDate":"2027-06-30"},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":["Endocarditis Infective"],"enrollment":360,"completionDate":"2027-12-30"},{"nctId":"NCT07202949","phase":"PHASE2","title":"A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2026-02-28","conditions":["Chronic Urinary Tract Infection"],"enrollment":192,"completionDate":"2027-11"},{"nctId":"NCT05274672","phase":"PHASE4","title":"Role of Prophylactic Postoperative Antibiotics in HoLEP","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2023-03-01","conditions":["Benign Prostatic Hyperplasia","Urinary Tract Infections"],"enrollment":0,"completionDate":"2025-02-20"},{"nctId":"NCT06537609","phase":"NA","title":"A Platform Trial for Gram Negative Bloodstream Infections","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2024-04-24","conditions":["Gram-negative Bacteremia"],"enrollment":2500,"completionDate":"2028-04"},{"nctId":"NCT04876131","phase":"PHASE4","title":"Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-30","conditions":["Complicated Urinary Tract Infection","Infection","Pediatric Infectious Disease"],"enrollment":452,"completionDate":"2028-05-16"},{"nctId":"NCT04538053","phase":"PHASE4","title":"BonE and Joint Infections - Simplifying Treatment in Children Trial","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-06-01","conditions":["Bone Infection","Septic Arthritis","Bone and Joint Infection","Osteomyelitis"],"enrollment":285,"completionDate":"2026-12"},{"nctId":"NCT06055712","phase":"PHASE4","title":"Antibiotic Prophylaxis in Pediatric Open Fractures","status":"ENROLLING_BY_INVITATION","sponsor":"St. Louis University","startDate":"2023-09-11","conditions":["Fractures, Open","Infections"],"enrollment":800,"completionDate":"2034-01"},{"nctId":"NCT05852262","phase":"PHASE4","title":"High-dose Cephalexin for Cellulitis (HI-DOCC)","status":"ENROLLING_BY_INVITATION","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-08-30","conditions":["Cellulitis"],"enrollment":446,"completionDate":"2026-08-01"},{"nctId":"NCT06127160","phase":"PHASE4","title":"Patient-Directed Antimicrobial Duration in Acute Uncomplicated Pyelonephritis","status":"COMPLETED","sponsor":"Brett A Faine","startDate":"2024-06-04","conditions":["Pyelonephritis Acute"],"enrollment":35,"completionDate":"2025-08-29"},{"nctId":"NCT05726318","phase":"PHASE4","title":"Randomized Trial of Culture Directed Versus Empiric Antibiotics for Urinary Tract Infections in Older Women","status":"COMPLETED","sponsor":"Megan Bradley","startDate":"2023-02-17","conditions":["UTI"],"enrollment":70,"completionDate":"2024-08-02"},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":["Endovascular Infection","Bone and Joint Infection","Skin and Soft Tissue Infection","Pulmonary Infection","Gastrointestinal Infection","Genitourinary Infection"],"enrollment":94,"completionDate":"2025-02-14"},{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":["Acute Bacterial Skin and Skin Structure Infections"],"enrollment":100,"completionDate":"2023-07-06"},{"nctId":"NCT04297592","phase":"PHASE4","title":"Antibiotic Prophylaxis in High-Risk Arthroplasty Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Mayo Clinic","startDate":"2020-06-11","conditions":["Infections Joint Prosthetic","Overweight or Obesity","MSSA Colonization","MRSA","Chronic Kidney Diseases","Diabetes","Autoimmune Diseases","Inflammatory Disease","Tobacco Use"],"enrollment":4618,"completionDate":"2026-06"},{"nctId":"NCT07032883","phase":"NA","title":"Benson Relaxation Technique Effectiveness on Pain and Quality of Life Post Reconstructive Mammoplasty","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-06-25","conditions":["Breast Cancer"],"enrollment":68,"completionDate":"2026-02-15"},{"nctId":"NCT06166667","phase":"NA","title":"Effect of Fecal Capsule on Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"Shanxi Provincial People's Hospital","startDate":"2023-03-01","conditions":["Renal Insufficiency, Chronic"],"enrollment":20,"completionDate":"2023-12-31"},{"nctId":"NCT01912651","phase":"PHASE4","title":"The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2013-07","conditions":["Facial Defect"],"enrollment":300,"completionDate":"2028-09"},{"nctId":"NCT02829060","phase":"NA","title":"Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2016-01","conditions":["Nephrolithiasis","Urinary Tract Infection (UTI)","Sepsis"],"enrollment":330,"completionDate":"2025-03"},{"nctId":"NCT04471246","phase":"PHASE4","title":"High-dose vs. Standard-dose Cephalexin for Cellulitis","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-08-16","conditions":["Cellulitis"],"enrollment":69,"completionDate":"2022-02-23"},{"nctId":"NCT00560651","phase":"","title":"German Corneal Cross Linking Register","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suphi Taneri","startDate":"2007-11","conditions":["Keratoconus"],"enrollment":7500,"completionDate":"2027-11"},{"nctId":"NCT04194216","phase":"PHASE3","title":"Antibiotic Prophylaxis in Rhinoplasty","status":"ENROLLING_BY_INVITATION","sponsor":"Stanford University","startDate":"2020-05-20","conditions":["Nasal Obstruction","Nasal Surgical Procedures"],"enrollment":864,"completionDate":"2027-04-20"},{"nctId":"NCT02014558","phase":"PHASE1,PHASE2","title":"Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2013-10-09","conditions":["Acute Myeloid Leukemia"],"enrollment":265,"completionDate":"2018-03-07"},{"nctId":"NCT06207786","phase":"NA","title":"Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery","status":"WITHDRAWN","sponsor":"Mayo Clinic","startDate":"2024-09-01","conditions":["Skin Cancer","Skin Cancer Face","Malignant Cutaneous Adnexal Neoplasm"],"enrollment":0,"completionDate":"2030-05"},{"nctId":"NCT05925309","phase":"NA","title":"Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2023-07-01","conditions":["Biliary Atresia","Cholangitis","Anti-Bacterial Agents"],"enrollment":356,"completionDate":"2027-07-31"},{"nctId":"NCT05893147","phase":"NA","title":"BALANCE+ Vanguard Phase","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2023-08-26","conditions":["Gram-negative Bacteremia"],"enrollment":174,"completionDate":"2024-08-10"},{"nctId":"NCT02814916","phase":"PHASE3","title":"Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-03-30","conditions":["Methicillin-Resistant Staphylococcus Aureus","Bacterial Infections","Staphylococcal Skin Infections"],"enrollment":199,"completionDate":"2024-01-01"},{"nctId":"NCT00835081","phase":"PHASE1","title":"Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-09","conditions":["Healthy"],"enrollment":26,"completionDate":"2004-10"},{"nctId":"NCT00834275","phase":"PHASE1","title":"Cefadroxil 500 mg Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-09","conditions":["Healthy"],"enrollment":26,"completionDate":"2004-10"},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":["Staphylococcus Aureus Bacteremia"],"enrollment":290,"completionDate":"2025-06"},{"nctId":"NCT04631185","phase":"NA","title":"Surgical Site Infection and Antibiotic Use Study","status":"COMPLETED","sponsor":"The Plastic Surgery Foundation","startDate":"2021-05-07","conditions":["Surgical Site Infection","Breast Reconstruction","Antibiotic Use"],"enrollment":235,"completionDate":"2024-05-20"},{"nctId":"NCT05519072","phase":"PHASE4","title":"Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA","status":"RECRUITING","sponsor":"Atlantic Health System","startDate":"2022-08-16","conditions":["Antibiotic Prophylaxis"],"enrollment":140,"completionDate":"2024-08-16"},{"nctId":"NCT06255652","phase":"","title":"Oral Versus Intravenous Antibiotic Prophylaxis Before Obstetric and Gynecological Procedures","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-10-01","conditions":["Site Infection"],"enrollment":1,"completionDate":"2024-07-31"},{"nctId":"NCT05719285","phase":"PHASE4","title":"Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2022-12-06","conditions":["Overactive Bladder","Overactive Bladder Syndrome","Urge Incontinence","Urinary Incontinence, Urge"],"enrollment":100,"completionDate":"2023-06-08"},{"nctId":"NCT04916951","phase":"PHASE1","title":"Oral Amoxicillin and Cephalexin PK/PD in Neonates","status":"UNKNOWN","sponsor":"University of Colorado, Denver","startDate":"2021-07-14","conditions":["Neonatal Infection"],"enrollment":60,"completionDate":"2024-06"},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":["Endocarditis"],"enrollment":20,"completionDate":"2024-10"},{"nctId":"NCT04409093","phase":"NA","title":"Eponychial Stent Study","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2020-06-01","conditions":["Eponychial Stent","Nail Bed Injury"],"enrollment":54,"completionDate":"2023-08-24"},{"nctId":"NCT03187106","phase":"PHASE1","title":"Prophylactic Antibiotics After Cesarean","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2017-08-01","conditions":["Surgical Site Infection"],"enrollment":321,"completionDate":"2023-07-21"},{"nctId":"NCT05664568","phase":"PHASE2","title":"The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis","status":"UNKNOWN","sponsor":"Western Sydney Local Health District","startDate":"2023-03-15","conditions":["Tuberculosis, Pulmonary"],"enrollment":30,"completionDate":"2024-12"},{"nctId":"NCT05702762","phase":"PHASE2","title":"Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting","status":"UNKNOWN","sponsor":"Mercy Health Ohio","startDate":"2022-10-01","conditions":["Urinary Tract Infections"],"enrollment":160,"completionDate":"2024-06-30"},{"nctId":"NCT03877289","phase":"PHASE4","title":"Efficacy of Oxybutynin in Paediatric Cystitis","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2008-10","conditions":["Cystitis"],"enrollment":81,"completionDate":"2014-07"},{"nctId":"NCT04834310","phase":"PHASE4","title":"Postoperative Antibiotics Following Primary and Secondary Breast Augmentation","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2021-04-01","conditions":["Surgical Site Infection","Capsular Contracture Associated With Breast Implant","Antibiotic Resistant Infection","Antibiotic Side Effect"],"enrollment":0,"completionDate":"2024-07-30"},{"nctId":"NCT02375295","phase":"PHASE4","title":"Struvite Stones Antibiotic Study","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2015-03","conditions":["Kidney Stones"],"enrollment":28,"completionDate":"2023-12"},{"nctId":"NCT02809131","phase":"PHASE3","title":"Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-04-01","conditions":["Sick Sinus Syndrome","Complete Heart Block","Syncope","Chronic Systolic Heart Failure"],"enrollment":1010,"completionDate":"2021-09-30"},{"nctId":"NCT03357419","phase":"NA","title":"The Effect of Prophylactic Antibiotics on Surgical Site Infection Lower Limb Skin Excisions","status":"WITHDRAWN","sponsor":"Rambam Health Care Campus","startDate":"2021-03","conditions":["Skin Lesion"],"enrollment":0,"completionDate":"2022-03-27"},{"nctId":"NCT05293977","phase":"NA","title":"Short-Term Use of Antibiotics and Adherence Level","status":"COMPLETED","sponsor":"Jordan University of Science and Technology","startDate":"2020-08-03","conditions":["Acute Infection"],"enrollment":589,"completionDate":"2021-12-15"},{"nctId":"NCT04553419","phase":"PHASE3","title":"Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2020-07-27","conditions":["Cystic Fibrosis"],"enrollment":86,"completionDate":"2025-06-30"},{"nctId":"NCT03802552","phase":"PHASE1","title":"Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2019-05-01","conditions":["Osteomyelitis","Septic Arthritis","Pyomyositis"],"enrollment":17,"completionDate":"2021-04-30"},{"nctId":"NCT02512198","phase":"NA","title":"Electronic Prescription Data to Improve Primary Care Prescribing","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2015-07","conditions":["Physician's Practice Patterns"],"enrollment":236,"completionDate":"2017-07-01"},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT04723940","phase":"PHASE3","title":"Or v IV Antibiotics for Infection","status":"UNKNOWN","sponsor":"Rothman Institute Orthopaedics","startDate":"2021-01-25","conditions":["Joint Infection"],"enrollment":308,"completionDate":"2023-01-25"},{"nctId":"NCT04285320","phase":"PHASE4","title":"Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections","status":"UNKNOWN","sponsor":"Atlantic Health System","startDate":"2021-03","conditions":["Recurrent Urinary Tract Infection"],"enrollment":100,"completionDate":"2023-04"},{"nctId":"NCT04413019","phase":"","title":"Domiciliary Versus Hospital Management of PPROM","status":"COMPLETED","sponsor":"Ahmed Mohammed Selim","startDate":"2019-04-15","conditions":["Preterm Premature Rupture of Membrane"],"enrollment":3662,"completionDate":"2020-10-20"},{"nctId":"NCT04577846","phase":"PHASE3","title":"SSI Rates in Patients Undergoing Mastectomy Without Reconstruction- A Multicenter, Double-blinded RCT.","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2020-11-01","conditions":["Surgical Site Infection"],"enrollment":384,"completionDate":"2022-12-31"},{"nctId":"NCT01595529","phase":"PHASE2","title":"The SCOUT Study: \"Short Course Therapy for Urinary Tract Infections in Children\"","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-05-18","conditions":["Urinary Tract Infection"],"enrollment":717,"completionDate":"2019-08-12"},{"nctId":"NCT01507974","phase":"NA","title":"Examination of the Efficacy of Preventive Antibiotic Treatment During the Puerperium Among Pregnant Women With Recurrent Urinary Tract Infections","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-01-16","conditions":["Pregnancy Complications"],"enrollment":220,"completionDate":"2015-01-01"},{"nctId":"NCT03275623","phase":"PHASE4","title":"Management of Sub-Clinical Bacteriuria in Pregnancy","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2017-09-15","conditions":["Cystitis","Cystitis;Puerperium","Pyelonephritis"],"enrollment":60,"completionDate":"2019-03-18"},{"nctId":"NCT02381470","phase":"PHASE2","title":"Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2019-02-11","conditions":["Pulmonary Tuberculosis"],"enrollment":58,"completionDate":"2019-10-02"},{"nctId":"NCT01899781","phase":"PHASE4","title":"Prophylactic Antibiotic Treatment for Hand Lacerations Involving Flexor and/or Extensor Tendon","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2013-08","conditions":["Hand Laceration","Tendon Involved","Clean Laceration","No Bone Involved"],"enrollment":24,"completionDate":"2015-11"},{"nctId":"NCT04146883","phase":"NA","title":"Post-procedure Antibiotic Prophylaxis for Cardiac Electrical Device Implantation: ABxFREE Study","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2019-08-20","conditions":["Post Procedural Infection","Pacemaker Electrode Infection","Antibiotics","Implantable Defibrillator User"],"enrollment":800,"completionDate":"2021-12-31"},{"nctId":"NCT02276482","phase":"PHASE3","title":"Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-03-25","conditions":["Skin Diseases, Infectious","Skin Diseases, Bacterial"],"enrollment":120,"completionDate":"2018-09-17"},{"nctId":"NCT02297815","phase":"","title":"Comparative Effectiveness of Antibiotics for Respiratory Infections","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2014-01","conditions":["Acute Otitis Media","Acute Sinusitis","Group A Streptococcal Pharyngitis"],"enrollment":2472,"completionDate":"2016-04"},{"nctId":"NCT01628666","phase":"PHASE4","title":"Prevention of Arrhythmia Device Infection Trial (PADIT)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2012-12","conditions":["Arrhythmia"],"enrollment":12814,"completionDate":"2017-09-08"},{"nctId":"NCT00957827","phase":"NA","title":"Prophylactic Use of Antibiotics for Through and Through Lacerations of the Lip","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2009-08","conditions":["Through-and-through Lip Lacerations"],"enrollment":4,"completionDate":"2011-08"},{"nctId":"NCT01500382","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-27","conditions":["Overactive Bladder","Overactive Urinary Bladder"],"enrollment":4,"completionDate":"2013-01-02"},{"nctId":"NCT03736187","phase":"NA","title":"Antibiotics for Prevention of SSI in Obese Women Undergoing CS","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-04","conditions":["Surgical Site Infection"],"enrollment":280,"completionDate":"2019-12"},{"nctId":"NCT01029782","phase":"PHASE2","title":"Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis","status":"COMPLETED","sponsor":"Kelowna General Hospital","startDate":"2010-05","conditions":["Cellulitis"],"enrollment":206,"completionDate":"2014-10"},{"nctId":"NCT03569969","phase":"NA","title":"Comparison Tympanoplasty With Membrane Amniotic and Autologous Fascia","status":"COMPLETED","sponsor":"Mohammad Sadegh Bagheri Baghdasht","startDate":"2016-01-01","conditions":["Tympanic Membrane Perforation"],"enrollment":30,"completionDate":"2017-12-01"},{"nctId":"NCT02569866","phase":"PHASE2","title":"Antibiotics After Breast Reduction:Clinical Trial With Randomization","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2014-11","conditions":["Surgical Site Infection"],"enrollment":124,"completionDate":"2016-08"},{"nctId":"NCT02911662","phase":"NA","title":"Treatment of Asymptomatic Bacteriuria in Pregnancy","status":"TERMINATED","sponsor":"Trinity Health Michigan","startDate":"2016-09","conditions":["Bacteriuria (Asymptomatic) in Pregnancy"],"enrollment":13,"completionDate":"2018-01"},{"nctId":"NCT02145338","phase":"PHASE4","title":"Antibiotic Prophylaxis for Clean Intermittent Catheterisation","status":"COMPLETED","sponsor":"Newcastle-upon-Tyne Hospitals NHS Trust","startDate":"2013-09","conditions":["Urinary Tract Infections, Recurrent"],"enrollment":404,"completionDate":"2017-02-22"},{"nctId":"NCT02446496","phase":"PHASE4","title":"A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-31","conditions":["Infections, Urinary Tract"],"enrollment":24,"completionDate":"2014-04-08"},{"nctId":"NCT01767584","phase":"PHASE1","title":"Bioequivalence Study of Cephalexin Tablets 1g","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-06","conditions":["Infections, Respiratory Tract"],"enrollment":26,"completionDate":"2009-04-14"},{"nctId":"NCT01767532","phase":"PHASE1","title":"Bioequivalence Study of Cephalexin Suspension 125","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-30","conditions":["Infections, Respiratory Tract"],"enrollment":28,"completionDate":"2011-02-08"},{"nctId":"NCT01767571","phase":"PHASE1","title":"Bioequivalence Study of Cephalexin Suspension 250","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-30","conditions":["Infections, Respiratory Tract"],"enrollment":28,"completionDate":"2011-02-08"},{"nctId":"NCT03148444","phase":"PHASE4","title":"Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome","status":"UNKNOWN","sponsor":"Kaplan Medical Center","startDate":"2017-06-01","conditions":["Infection, Bacterial","Pacemaker Complication"],"enrollment":400,"completionDate":"2020-06-01"},{"nctId":"NCT01899690","phase":"PHASE4","title":"Antibiotics and Tissue Expanders in Breast Reconstruction","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2016-06","conditions":["Complications; Breast Prosthesis, Infection or Inflammation"],"enrollment":0,"completionDate":"2017-12"},{"nctId":"NCT01561703","phase":"NA","title":"Comparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2012-03","conditions":["Snoring","Strep Throat"],"enrollment":58,"completionDate":"2015-06"},{"nctId":"NCT02490670","phase":"PHASE1","title":"A Study of Cephalexin Liquid in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-07","conditions":["Healthy"],"enrollment":28,"completionDate":"2015-07"},{"nctId":"NCT00895089","phase":"PHASE4","title":"Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2009-05","conditions":["Liver Abscess"],"enrollment":24,"completionDate":"2011-12"},{"nctId":"NCT02140281","phase":"PHASE1","title":"To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers","status":"COMPLETED","sponsor":"Ardelyx","startDate":"2014-05","conditions":["Healthy Volunteers"],"enrollment":71,"completionDate":"2014-08"},{"nctId":"NCT02123446","phase":"PHASE1","title":"A Study of Cephalexin Capsules in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":["Healthy Volunteers"],"enrollment":28,"completionDate":"2014-05"},{"nctId":"NCT02123472","phase":"PHASE1","title":"A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-05","conditions":["Healthy Volunteers"],"enrollment":28,"completionDate":"2014-05"},{"nctId":"NCT02479867","phase":"PHASE1","title":"A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2014-03","conditions":["Healthy"],"enrollment":24,"completionDate":"2014-04"},{"nctId":"NCT01229553","phase":"NA","title":"Effect of Topical and Systemic Decolonization of Staphylococcus Aureus (SA) in Pediatric Cystic Fibrosis (CF) Patients","status":"WITHDRAWN","sponsor":"State University of New York - Upstate Medical University","startDate":"2011-01","conditions":["Cystic Fibrosis"],"enrollment":0,"completionDate":"2011-01"},{"nctId":"NCT02123459","phase":"PHASE1","title":"A Study of Cephalexin Suspension in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-05","conditions":["Healthy Volunteers"],"enrollment":28,"completionDate":"2014-05"},{"nctId":"NCT02100826","phase":"PHASE1","title":"A Study of Cephalexin in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-04","conditions":["Healthy Volunteers"],"enrollment":28,"completionDate":"2014-05"},{"nctId":"NCT00187759","phase":"NA","title":"Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2004-11","conditions":["Soft Tissue Infections"],"enrollment":500,"completionDate":"2005-03"},{"nctId":"NCT00300092","phase":"PHASE2","title":"Pediatric Fingertip Injuries:Are Antibiotics Required?","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2000-09","conditions":["Finger Injuries"],"enrollment":146,"completionDate":"2004-07"},{"nctId":"NCT01073553","phase":"PHASE1","title":"Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-10","conditions":["Anti-Infective Agents"],"enrollment":26,"completionDate":"2009-10"},{"nctId":"NCT00729937","phase":"PHASE2,PHASE3","title":"Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus \"STOP MRSA\"","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-04","conditions":["Staphylococcal Infection"],"enrollment":2265,"completionDate":"2013-06"},{"nctId":"NCT01823523","phase":"NA","title":"Orthognathic Surgery and Postoperative Antibiotic Use","status":"UNKNOWN","sponsor":"Atlantic Center for Oral and Maxillofacial Surgery","startDate":"2013-06","conditions":["Dentofacial Deformity"],"enrollment":300,"completionDate":"2015-10"},{"nctId":"NCT01400867","phase":"PHASE2,PHASE3","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12","conditions":["Infections, Pediatrics"],"enrollment":163,"completionDate":"2014-07"},{"nctId":"NCT01155154","phase":"NA","title":"Antibiotic Prophylaxis for Simple Hand Lacerations","status":"TERMINATED","sponsor":"State University of New York - Downstate Medical Center","startDate":"2010-02","conditions":["Simple Hand Lacerations"],"enrollment":73,"completionDate":"2012-02"},{"nctId":"NCT01613092","phase":"PHASE4","title":"Prevention of Arrhythmia Device Infection Trial (PADIT)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2011-05","conditions":["Arrhythmia"],"enrollment":241,"completionDate":"2013-12"},{"nctId":"NCT01105208","phase":"PHASE1","title":"Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-03","conditions":["Anti-Infective Agents"],"enrollment":26,"completionDate":"2010-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, For Suspension, Powder, Suspension","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"CEPHALEXIN"},{"form":"CAPSULE","route":"ORAL","productName":"Cephalexin"},{"form":"CAPSULE","route":"ORAL","productName":"KEFLEX"},{"form":"CAPSULE","route":"ORAL","productName":"cephalexin"},{"form":"FOR SUSPENSION","route":"ORAL","productName":"CEPHALEXIN"},{"form":"FOR SUSPENSION","route":"ORAL","productName":"Cephalexin"},{"form":"FOR SUSPENSION","route":"ORAL","productName":"cephalexin"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"CEPHALEXIN"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"CEPHALEXIN ORAL SUSP"},{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"Cephalexin"},{"form":"SUSPENSION","route":"ORAL","productName":"CEPHALEXIN"},{"form":"SUSPENSION","route":"ORAL","productName":"Cephalexin"},{"form":"SUSPENSION","route":"ORAL","productName":"CephalexinUSP"},{"form":"TABLET","route":"ORAL","productName":"Cephalexin"}]},"crossReferences":{"NUI":"N0000179741","MMSL":"4393","NDDF":"002716","UNII":"OBN7UDS42Y","VUID":"4018893","CHEBI":"CHEBI:3534","VANDF":"4018891","INN_ID":"2400","RXNORM":"1299782","UMLSCUI":"C0007716","chemblId":"CHEMBL1200544","ChEMBL_ID":"CHEMBL1727","KEGG_DRUG":"D00263","DRUGBANK_ID":"DB00567","PUBCHEM_CID":"27447","SNOMEDCT_US":"387304003","IUPHAR_LIGAND_ID":"4832","SECONDARY_CAS_RN":"23325-78-2","MESH_DESCRIPTOR_UI":"D002506"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1971-","companyName":"Shionogi Inc","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.57 hours","clearance":"3.9 mL/min/kg","bioavailability":"90%","fractionUnbound":"0.85%","volumeOfDistribution":"0.21 L/kg"},"publicationCount":468,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DB01","allCodes":["J01DB01"]},"biosimilarFilings":[],"originalDeveloper":"Shionogi Inc","recentPublications":[{"date":"2025 Oct 10","pmid":"41759466","title":"Epidemiological investigation and antimicrobial resistance profiling of Salmonella in broiler chickens with assessment of Lactococcus lactis probiotic therapy.","journal":"Poultry science"},{"date":"2026 Feb 2","pmid":"41744033","title":"Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence.","journal":"The Journal of antimicrobial chemotherapy"},{"date":"2026 May 1","pmid":"41719646","title":"Structure-dependent transformation of cephalosporin antibiotics at MnO(2) surface mediated by iodide and formation of highly toxic iodinated products.","journal":"Water research"},{"date":"2025","pmid":"41602617","title":"Antimicrobial use in breeding kennels and antimicrobial resistance profile of Escherichia coli and Staphylococcus pseudintermedius isolated from healthy breeding bitches in Northern Italy.","journal":"Frontiers in veterinary science"},{"date":"2025 Dec 26","pmid":"41485905","title":"Trends in Group A Streptococcus Isolation and Antimicrobial Susceptibility in a Pediatric Population (2021-2023): Comparison with Six Previous Surveys.","journal":"Japanese journal of infectious diseases"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Shionogi","companyId":"shionogi","modality":"Small Molecule","firstApprovalDate":"1971","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:28:59.768490+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}